BRAF and melanoma: Further, we performed chemosensitivity arrays 72 h after treatment of SKMEL28 and 451LU melanoma cells (both carrying a BRAF mutation) with the BRAF-antagonist dabrafenib in combination with the MEK-inhibitor trametinib in combination with agonists and antagonists.